ALSPW Spineway SAS

Strengthened presence in Europe

Strengthened presence in Europe

Press release        Ecully, July 8, 2024 – 8 a.m.



Spineway continues its sales and marketing efforts in Europe

The Spineway Group, a specialist in innovative implants for the treatment of severe spine disorders, announces that it participated in the , the annual congress of the Spanish Spine Society, held in Malaga in May.

GEER is the annual meeting of spine surgeons in Spain, like the held in Montpellier at the beginning of June.1 Spineway’s participation in these two international congresses allowed the company to develop new training partnerships and to increase its visibility and position in key European markets. At the SFCR Congress, Spineway recruited a new agent to strengthen its presence in the Paris-South and North-West regions, with a view to eventually covering the whole of France.



At GEER, Spineway was present alongside its two distribution partners, the and . Palex is a major player in import and distribution in Spain (€1 billion in revenue). Active in all medical and surgical specialties, it is responsible for expanding sales of Spineway’s arthrodesis ranges in Spain (in particular the VEOS system). Technospine is responsible for distributing the Group’s ESP disc prostheses in Spain. 

During the congress, Stéphane Le Roux, Group CEO, and Fabrice Paccagnella, Global Sales Director, accompanied by members of the sales and marketing team, presented the VEOS and ACIFBOX ranges and the Group’s latest innovations to the Spanish surgical community.

Europe has become the 2nd sales territory since July 2022 (over 50%), thanks to the acquisitions of Distimp in 2021 and Spine Innovations in July 2022, whose products meet the needs of spine surgeons. The next major event for Spineway will be the SILACO Congress in Mexico, from July 24 to 27, which will bring together spine surgeons from Latin and South America.

Spineway plans to continue its expansion in Europe and confirms its aim of becoming a major player in less invasive spine treatments.

Next event:

July 15, 2024 – H1 2024 revenue

July 24 to 27, 2024 – SILACO Congress in Mexico

SPINEWAY IS ELIGIBLE FOR PEA-SME (EQUITY SAVINGS PLANS FOR SMES)

Find out all about Spineway at

This press release has been prepared in both English and French. In case of discrepancies, the French version shall prevail.

Spineway designs, manufactures and markets innovative implants and surgical instruments for treating severe disorders of the spinal column.

Spineway has an international network of independent distributors and derives more than 70% of its revenue from exports.

ISIN: FR001400BVK2 – ALSPW        

Contacts:

SPINEWAY GROUP



Shareholder-services line



Available Tuesday through Thursday



+33 (0)806 706 060
Eligible PEA / PME





ALSPW





Euronext Growth

AELIUM



Finance & Communication







Investor relations



Solène Kennis






1 Press release of June 10, 2024

Attachment



EN
08/07/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Spineway SAS

 PRESS RELEASE

Spineway : a week dedicated to medical excellence with more than 20 su...

Spineway : a week dedicated to medical excellence with more than 20 surgeons trained Press release         Ecully, November 14, 2024 – 6 p.m. Spineway: a week dedicated to medical excellence with more than 20 surgeons trained The Spineway Group, a , specialist in innovative implants for the treatment of severe spine disorders, organized a week of training dedicated to medical education from November 4 to 8, 2024. Through practical sessions in the operating room and on anatomical specimens in the laboratory, this intensive program trained over 20 international surgeons in the use of the G...

 PRESS RELEASE

SPINEWAY : une semaine au service de l'Excellence Médicale avec plus d...

SPINEWAY : une semaine au service de l'Excellence Médicale avec plus de 20 chirurgiens formés Communiqué de presse          Ecully, le 14 novembre 2024 – 18h Spineway : une semaine au service de l'Excellence Médicale avec plus de 20 chirurgiens formés Le groupe Spineway, spécialiste des implants innovants pour le traitement des pathologies sévères de la colonne vertébrale (rachis), a organisé une semaine de formation dédiée à l’éducation médicale du 4 au 8 novembre 2024. À travers des sessions pratiques en bloc opératoire et sur pièces anatomiques en laboratoire, ce programme intensif a ...

 PRESS RELEASE

Spineway generates great interest at the EUROSPINE 2024 Congress in Vi...

Spineway generates great interest at the EUROSPINE 2024 Congress in Vienna Press release       Ecully, October 22, 2024 – 6 p.m. Spineway generates great interest at the EUROSPINE 2024 Congress in Vienna The Spineway Group, a specialist in innovative implants for the treatment of severe spine disorders, took part in the , Europe’s leading spine conference, held from October 2 to 4, in Vienna, Austria. During the event, which brought together more than 3,500 spine surgeons and professionals from all over the world, Spineway enjoyed a prime location in the heart of the Messe Wien congr...

 PRESS RELEASE

Spineway : Continued organic growth - Nine-month 2024 revenue of €9.1 ...

Spineway : Continued organic growth - Nine-month 2024 revenue of €9.1 million (+21%) Press release         Ecully, October 15, 2024 – 6 p.m. SPINEWAY Continued organic growthNine-month 2024 revenue of €9.1 million (+21%) In thousands of euros20242023Change %Q1 revenue3,0702,39828%Q2 revenue3,4653,03314%Q3 revenue2,5752,07724%9M revenue9,1107,51021% Unaudited consolidated data The Spineway Group, a specialist in innovative implants for the treatment of severe spine disorders, recorded an excellent third quarter in 2024, with revenue of €2.6 million, representing purely organic growth (...

 PRESS RELEASE

SPINEWAY : Poursuite de la croissance organique - Chiffre d’affaires à...

SPINEWAY : Poursuite de la croissance organique - Chiffre d’affaires à 9 mois 2024 de 9,1 M€ (+ 21%) Communiqué de presse          Ecully, le 15 octobre 2024 –18h SPINEWAY Poursuite de la croissance organiqueChiffre d’affaires à 9 mois 2024 de 9,1 M€ (+ 21%) En milliers d’euros20242023Variation en %CA 1er trimestre3 0702 398+ 28%CA 2ème trimestre3 4653 033+ 14%CA 3ème trimestre2 5752 077+ 24%CA 9 mois9 1107 510+ 21% Données consolidées non auditées Spineway, spécialiste des implants innovants pour le traitement des pathologies sévères de la colonne vertébrale (rachis), a réalisé un t...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch